Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.
Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.
复制标题
DOI：
10.3389/fimmu.2017.01779
复制
发表时间：
2017
影响因子：
7.3
通讯作者：
Ali N
中科院分区：
文献类型：
--
作者：
Didwania N;Shadab M;Sabur A;Ali N
利什曼病是一种被忽视的原虫病，主要影响世界热带和亚热带国家。控制这种疾病的主要选择仍然依赖于化疗。然而，由于耐药寄生虫的出现、药物的巨大副作用、高昂的费用以及需要长期住院治疗，阻碍了治疗，这增加了利什曼病控制规划的现有问题。这篇综述强调了免疫治疗和/或免疫化疗的前景，以解决目前利什曼病治疗措施的局限性。除了在替代治疗策略方面取得进展外，还指出了制定预防措施的可能性和进展。这篇综述强调了我们最近对保护性免疫学的理解，可用于开发对抗利什曼病的有效疫苗。此外，还讨论了近年来发展起来的方法的最新情况，这些方法主要集中在克服目前在开发免疫治疗和预防性抗利什曼疫苗方面的挑战。
Leishmaniasis is a neglected protozoan disease that mainly affects the tropical as well as subtropical countries of the world. The primary option to control the disease still relies on chemotherapy. However, a hindrance to treatments owing to the emergence of drug-resistant parasites, enormous side effects of the drugs, their high cost, and requirement of long course hospitalization has added to the existing problems of leishmaniasis containment program. This review highlights the prospects of immunotherapy and/or immunochemotherapy to address the limitations for current treatment measures for leishmaniasis. In addition to the progress in alternate therapeutic strategies, the possibility and advances in developing preventive measures against the disease have been pointed. The review highlights our recent understandings of the protective immunology that can be exploited to develop an effective vaccine against leishmaniasis. Moreover, an update on the approaches that have evolved over the recent years are predominantly focused to overcome the current challenges in developing immunotherapeutic as well as prophylactic antileishmanial vaccines is discussed.